Territorial Availability: Available through Bertin Technologies only in France
- Synonyms
- 2,5-dihydro-4-hydroxy-5-oxo-1-(phenylmethyl)-1H-pyrrole-3-carboxylic acid, ethyl ester
- Correlated keywords
- metabolisms metabolic syndromes enzymes activity activities glucose diabetes PGF2? synthases aldoses reductases AKR1B1 sorbitol inhibitors drugs resistances cancers inhibits inhibitions improve cytotoxic effects anti-cancer anti cisplatin HeLa cervical carcinomas prostaglandins PGE2 potent NSC-229530 NSC229530 humans enzymes polyol pathways IL-1? IL-1.beta. IL-1B interleukins interleukin-1? interleukin-1B expressions diabetes chemotherapy chemotherapeutics in vitro doxorubicin cisplatin cells endometrial
- Product Overview:
The human aldose reductase AKR1B1 is considered the rate limiting enzyme of the polyol pathway responsible for the conversion of glucose into sorbitol. It also acts as a highly efficient PGF2? synthase in response to interleukin-1?.{22416} Increased aldose reductase expression has been associated with complications of diabetes and may contribute to reduced efficacy of certain chemotherapeutic drugs.{22417} EBPC is a potent, selective inhibitor of aldose reductase with an IC50 value of 47 nM in vitro.{22415} Through its regulation of glucose metabolism, EBPC has been used to improve the cytotoxic effects of the anticancer agents doxorubicin and cisplatin in HeLa cervical carcinoma cells.{22417} EBPC also inhibits prostaglandin F2? (PGF2?) and PGE2 production in human endometrial cells with an EC50 value of 10 ?M.{22416}
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.